23.97
price up icon0.38%   0.09
after-market After Hours: 24.00 0.03 +0.13%
loading
Pfizer Inc stock is traded at $23.97, with a volume of 62.62M. It is up +0.38% in the last 24 hours and up +1.91% over the past month. Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding covid-19-related product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.
See More
Previous Close:
$23.88
Open:
$24
24h Volume:
62.62M
Relative Volume:
1.29
Market Cap:
$138.15B
Revenue:
$62.46B
Net Income/Loss:
$7.88B
P/E Ratio:
17.37
EPS:
1.38
Net Cash Flow:
$11.22B
1W Performance:
-2.32%
1M Performance:
+1.91%
6M Performance:
-9.07%
1Y Performance:
-13.59%
1-Day Range:
Value
$23.77
$24.09
1-Week Range:
Value
$23.77
$24.59
52-Week Range:
Value
$20.91
$31.54

Pfizer Inc Stock (PFE) Company Profile

Name
Name
Pfizer Inc
Name
Phone
(212) 733-2323
Name
Address
66 HUDSON BOULEVARD EAST, NEW YORK, NY
Name
Employee
81,000
Name
Twitter
@Pfizer
Name
Next Earnings Date
2025-02-04
Name
Latest SEC Filings
Name
PFE's Discussions on Twitter

Compare PFE with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Drug Manufacturers - General icon
PFE
Pfizer Inc
23.97 138.15B 62.46B 7.88B 11.22B 1.38
Drug Manufacturers - General icon
LLY
Lilly Eli Co
762.73 724.64B 49.00B 11.11B -1.27B 12.29
Drug Manufacturers - General icon
JNJ
Johnson Johnson
149.79 376.43B 89.33B 21.81B 18.57B 8.99
Drug Manufacturers - General icon
NVO
Novo Nordisk Adr
73.77 352.49B 43.59B 15.04B 10.74B 3.3766
Drug Manufacturers - General icon
ABBV
Abbvie Inc
185.30 334.73B 57.37B 4.20B 15.39B 2.35
Drug Manufacturers - General icon
NVS
Novartis Ag Adr
115.77 234.21B 53.22B 12.86B 14.85B 6.39

Pfizer Inc Stock (PFE) Upgrades & Downgrades

Date Action Analyst Rating Change
Apr-22-25 Initiated Cantor Fitzgerald Neutral
Dec-10-24 Resumed BofA Securities Neutral
Nov-15-24 Initiated Wolfe Research Underperform
Oct-25-24 Resumed Citigroup Neutral
Oct-17-24 Initiated Bernstein Mkt Perform
Aug-07-24 Upgrade Daiwa Securities Neutral → Outperform
Mar-22-24 Downgrade Argus Buy → Hold
Feb-23-24 Initiated Guggenheim Buy
Jan-04-24 Downgrade TD Cowen Outperform → Market Perform
Oct-20-23 Resumed UBS Neutral
Oct-16-23 Upgrade Jefferies Hold → Buy
Jul-17-23 Reiterated JP Morgan Neutral
Jul-14-23 Initiated HSBC Securities Buy
Jun-29-23 Downgrade Credit Suisse Outperform → Neutral
May-11-23 Downgrade Daiwa Securities Outperform → Neutral
Mar-06-23 Initiated Jefferies Hold
Feb-07-23 Upgrade Daiwa Securities Neutral → Outperform
Jan-26-23 Downgrade UBS Buy → Neutral
Jan-17-23 Downgrade Wells Fargo Overweight → Equal Weight
Jan-04-23 Downgrade BofA Securities Buy → Neutral
Dec-13-22 Upgrade Goldman Neutral → Buy
Nov-18-22 Initiated Credit Suisse Outperform
May-23-22 Initiated SVB Leerink Mkt Perform
Apr-06-22 Resumed Morgan Stanley Equal-Weight
Jan-05-22 Upgrade BofA Securities Neutral → Buy
Jan-03-22 Reiterated Bernstein Mkt Perform
Dec-20-21 Reiterated Cowen Outperform
Dec-17-21 Initiated Goldman Neutral
Dec-13-21 Upgrade UBS Neutral → Buy
Dec-09-21 Initiated Wells Fargo Overweight
Nov-19-21 Initiated BMO Capital Markets Outperform
Jul-27-21 Resumed Truist Buy
May-06-21 Downgrade Mizuho Buy → Neutral
Apr-07-21 Resumed RBC Capital Mkts Sector Perform
Feb-04-21 Upgrade DZ Bank Hold → Buy
Dec-16-20 Downgrade RBC Capital Mkts Outperform → Sector Perform
Nov-19-20 Resumed Goldman Neutral
Nov-10-20 Resumed Bernstein Mkt Perform
Oct-12-20 Downgrade Atlantic Equities Overweight → Neutral
Sep-29-20 Initiated Berenberg Hold
Jun-16-20 Initiated SVB Leerink Mkt Perform
Feb-27-20 Initiated Barclays Equal Weight
Feb-27-20 Upgrade Standpoint Research Hold → Buy
Feb-06-20 Initiated Mizuho Buy
Jan-07-20 Initiated RBC Capital Mkts Outperform
Oct-17-19 Resumed BofA/Merrill Neutral
Jul-30-19 Downgrade BofA/Merrill Buy → Neutral
Jul-30-19 Downgrade Morgan Stanley Overweight → Equal-Weight
Jun-04-19 Resumed Morgan Stanley Overweight
Feb-20-19 Resumed Citigroup Neutral
Jan-31-19 Upgrade Argus Hold → Buy
Jan-31-19 Upgrade Credit Suisse Neutral → Outperform
Jan-23-19 Downgrade UBS Buy → Neutral
Dec-11-18 Downgrade JP Morgan Overweight → Neutral
Nov-01-18 Downgrade BMO Capital Markets Outperform → Market Perform
View All

Pfizer Inc Stock (PFE) Latest News

pulisher
Jun 19, 2025

Pfizer Secures Global Licensing Rights Outside China for 3SBio’s PD-1 and VEGF Targeting Antibody SSGJ-707 - geneonline.com

Jun 19, 2025
pulisher
Jun 18, 2025

Transcript : Pfizer Inc.Special Call - MarketScreener

Jun 18, 2025
pulisher
Jun 18, 2025

Is Pfizer Stock a Buy for Its Massive 7% Dividend Yield? A Trader’s Look - Daily Chhattisgarh News

Jun 18, 2025
pulisher
Jun 17, 2025

Pfizer Secures Global Licensing Rights Outside China for 3SBio’s Dual-Target Cancer Therapy SSGJ-707 - geneonline.com

Jun 17, 2025
pulisher
Jun 17, 2025

Global Drugmakers Tap Chinese Biotech for Novel Cancer Therapies - Caixin Global

Jun 17, 2025
pulisher
Jun 17, 2025

Lawmakers refresh tax-dodging accusations against Big Pharma, targeting Pfizer, AbbVie and others - Fierce Pharma

Jun 17, 2025
pulisher
Jun 17, 2025

Pfizer’s $6.15B 3Sbio deal tops May’s biopharma activity - BioWorld MedTech

Jun 17, 2025
pulisher
Jun 17, 2025

Democrats press Pfizer, J&J and others over low tax bills and lobbying as Senate debates Trump's plan - CNBC

Jun 17, 2025
pulisher
Jun 17, 2025

Should Value Investors Buy Pfizer (PFE) Stock? - Nasdaq

Jun 17, 2025
pulisher
Jun 17, 2025

Targeted cancer drugs may replace chemo for some patients — and drugmakers say they're getting closer - CNBC

Jun 17, 2025
pulisher
Jun 16, 2025

Pfizer Secures Global Rights Outside China for 3SBio’s Dual-Target Cancer Therapy SSGJ-707 - geneonline.com

Jun 16, 2025
pulisher
Jun 16, 2025

Non-Muscle Invasive Bladder Cancer Market Set to Grow Substantially Through 2034, DelveInsight Projects | CG Oncology, Pfizer, UroGen Pharma, Janssen Research & Development, LLC, Protara Therapeutics - The Globe and Mail

Jun 16, 2025
pulisher
Jun 15, 2025

Pfizer CEO Mentioned No Drug Price Commitments by Pfizer Inc. (PFE) - MSN

Jun 15, 2025
pulisher
Jun 15, 2025

Pfizer Inc. (NYSE:PFE) Is Going Strong But Fundamentals Appear To Be Mixed : Is There A Clear Direction For The Stock? - Yahoo Finance

Jun 15, 2025
pulisher
Jun 15, 2025

Goldman Sachs Maintains a Hold Rating on Pfizer (NYSE:PFE), Retains $27 PT - Insider Monkey

Jun 15, 2025
pulisher
Jun 15, 2025

Pfizer (PFE) Stock: Analyst Targets Suggest 15% Upside as Company Touts Strong Margins and Dividend - Daily Chhattisgarh News

Jun 15, 2025
pulisher
Jun 14, 2025

FDA Denies Pfizer's (PFE) Label Expansion for Talzenna in Prosta - GuruFocus

Jun 14, 2025
pulisher
Jun 14, 2025

Pfizer bid to expand Talzenna label faces FDA snub (PFE:NYSE) - Seeking Alpha

Jun 14, 2025
pulisher
Jun 14, 2025

Pfizer Secures Global Licensing Rights for 3SBio’s Dual-Target Cancer Therapy Excluding China - geneonline.com

Jun 14, 2025
pulisher
Jun 14, 2025

Pfizer (PFE) Option Activity Shows Mixed Sentiment | PFE Stock N - GuruFocus

Jun 14, 2025
pulisher
Jun 14, 2025

Pfizer’s SWOT analysis: stock outlook amid pipeline progress, cost cuts - Investing.com

Jun 14, 2025
pulisher
Jun 13, 2025

Pfizer : Provides Update on U.S. Regulatory Review of TALZENNA in Combination with XTANDI for Broader Use in Metastatic Castration-Resistant Prostate Cancer - MarketScreener

Jun 13, 2025
pulisher
Jun 13, 2025

Young minds dive into discovery at Pfizer School of Science Mobile Experience - Yahoo

Jun 13, 2025
pulisher
Jun 13, 2025

Pfizer’s 2024 Impact Report Highlights Accomplishments in Sustainability, Responsibility - Pfizer

Jun 13, 2025
pulisher
Jun 13, 2025

BioNTech’s CureVac Deal Signals Deep Pivot Toward mRNA Cancer Therapies - Investing.com

Jun 13, 2025
pulisher
Jun 13, 2025

Pfizer (PFE) Stock Shows Strong Rebound with Over 8% Monthly Gain, Halting Longer-Term Slide - Daily Chhattisgarh News

Jun 13, 2025
pulisher
Jun 13, 2025

Graft vs Host Disease Pipeline 2025: FDA Approvals and Clinical Trials Landscape with MOA and ROA Highlights by DelveInsight | Cellestia Biotech, Pfizer, Chia Tai Tianqing Pharma, Regimmune Corp - The Globe and Mail

Jun 13, 2025
pulisher
Jun 12, 2025

PFIZER INC : UBS remains Neutral - MarketScreener

Jun 12, 2025
pulisher
Jun 12, 2025

INVESTIGATION ALERT: Berger Montague PC Investigates Pfizer Inc.’s Board Of Directors For ... - Bluefield Daily Telegraph

Jun 12, 2025
pulisher
Jun 12, 2025

Why Apple, Microsoft, Pfizer and other U.S. multinational corporations set up shop in Ireland - CNBC

Jun 12, 2025
pulisher
Jun 12, 2025

4 Cheap Dividend Stocks Under $50 That Keep Raising Payouts - 24/7 Wall St.

Jun 12, 2025
pulisher
Jun 12, 2025

Pfizer (PFE) Sees Mixed Options Sentiment Amidst Modest Share In - GuruFocus

Jun 12, 2025
pulisher
Jun 11, 2025

Kennedy replaces fired US CDC panel members, includes anti-vaccine proponents - marketscreener.com

Jun 11, 2025
pulisher
Jun 11, 2025

Pharma 50: The top pharma companies in the world for 2025 - drugdiscoverytrends.com

Jun 11, 2025
pulisher
Jun 11, 2025

Pfizer Scraps Bid for Depo-Provera Mass Tort Following Dismissal of Most Phila. Plaintiffs - Law.com

Jun 11, 2025
pulisher
Jun 11, 2025

Cantor Fitzgerald Remains a Hold on Pfizer (PFE) - The Globe and Mail

Jun 11, 2025
pulisher
Jun 11, 2025

Pfizer says drugmakers met with Trump admin to discuss lowering drug prices - Yahoo Finance

Jun 11, 2025
pulisher
Jun 11, 2025

Request for Proposals: Pfizer Independent Research Grant Program 2025 - fundsforNGOs

Jun 11, 2025
pulisher
Jun 10, 2025

10 Best Wide Moat Stocks To Buy Now - Insider Monkey

Jun 10, 2025
pulisher
Jun 10, 2025

Xilio Therapeutics Appoints Akintunde Bello, Ph.D., to its Board of Directors - The Globe and Mail

Jun 10, 2025
pulisher
Jun 10, 2025

Why China Biotech Is Getting a DeepSeek Moment, Too - Bloomberg.com

Jun 10, 2025
pulisher
Jun 10, 2025

Pfizer Settles With Final Defendant in Mektovi Patent Lawsuit - Bloomberg Law News

Jun 10, 2025
pulisher
Jun 10, 2025

Pfizer Stock Rallies Over 8% in a Month, but Faces Long-Term Headwinds - Daily Chhattisgarh News

Jun 10, 2025
pulisher
Jun 10, 2025

Why Moderna, Pfizer Stocks Are Shrugging Off RFK Jr.’s Firing of Vaccine Advisors. - Barron's

Jun 10, 2025
pulisher
Jun 10, 2025

Top Cancer Stocks to Supercharge Your 2025 Portfolio - Yahoo Finance

Jun 10, 2025
pulisher
Jun 10, 2025

Wall Street Analysts Love These Ultra-High Yield Dividend Stocks - 24/7 Wall St.

Jun 10, 2025
pulisher
Jun 10, 2025

Vaccine stocks muted as Wall Street takes 'wait and watch' approach after Kennedy's shake-up - marketscreener.com

Jun 10, 2025
pulisher
Jun 10, 2025

Cantor Fitzgerald holds Pfizer stock at Neutral with $24 target By Investing.com - Investing.com India

Jun 10, 2025
pulisher
Jun 10, 2025

Pfizer: Dividend Investor's Dream And Patent Cliff Nightmare (NYSE:PFE) - Seeking Alpha

Jun 10, 2025
pulisher
Jun 09, 2025

No drug price pledges by Pfizer, others in talks with US government, Pfizer CEO says - Reuters

Jun 09, 2025
pulisher
Jun 09, 2025

Pfizer CEO Reportedly Says Company Made No Drug Price Pledges In Meeting With Trump Administration: Retail Sentiment Improves By Stocktwits - Investing.com India

Jun 09, 2025

Pfizer Inc Stock (PFE) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$108.50
price up icon 0.46%
drug_manufacturers_general SNY
$47.86
price up icon 0.50%
$289.33
price down icon 0.10%
drug_manufacturers_general MRK
$79.06
price down icon 0.29%
drug_manufacturers_general NVS
$115.77
price down icon 0.16%
Cap:     |  Volume (24h):